BMC Psychiatry
August 11, 2023
Abstract: Background: Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. In pooled analyses of two pivotal phase 3 studies, ASPIRE I and II, remission rates were consistently higher among patients with MDD with active suicidality who...
Bipolar Disorders
August 10, 2023
Renato de Filippis received travel grants and/or speaker/consultant fees from Janssen-Cilag. Pasquale De Fazio declares that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Please...
CNS Drugs
August 9, 2023
Meredith Castro, Samuel T. Wilkinson, Rayan K. Al Jurdi et al.
Background: Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 evaluated patients with TRD who received a second induction (IND) and maintenance treatment with ESK...
Current Medical Research and Opinion
August 3, 2023
OBJECTIVE: To describe access and real-world use patterns of esketamine nasal spray among adults with treatment-resistant depression (TRD) with private or public insurance. METHODS: Adults with ≥1 claim for esketamine nasal spray were selected from Clarivate's Real World Data product (January 2016-March 2021). Patients with evidence of TRD initiating esketamine (index date) after 05 March 2019...
JAMA Network Open
August 1, 2023
Chunfeng Xiao, Jia Zhou, Anning Li et al.
Importance: Loss of a previously effective response while still using adequate antidepressant treatment occurs in a relatively high proportion of patients with major depressive disorder (MDD); therefore, there is a need to develop novel effective treatment strategies. Objective: To assess the efficacy and safety of a single subanesthetic dose of esketamine in boosting the efficacy of oral...
Psychiatry Research
July 29, 2023
Mauro Pettorruso, Roberto Guidotti, Giacomo D’andrea et al.
56 citations
Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data about predictors of response are still lacking. Thus, a tool that can predict the individual patients' probability of response to ESK-NS is needed. This study investigates sociodemographic and...
Computational and Mathematical Methods in Medicine
July 26, 2023
Computational And Mathematical Methods In Medicine
[This retracts the article DOI: 10.1155/2022/1524198.].
Neuropsychiatric Disease and Treatment
July 17, 2023
Cheng-Chuan Chen, Xiao-Bin Wang
Thank you very much for your attention and advice, as this is indeed a thought-provoking issue. Although the US Food and Drug Administration (FDA) has not yet recognized the advantages of ketamine in treating depression and preventing suicide, relevant research results show that ketamine also has a significant role in preventing suicide. In contrast, as the only drug approved by the FDA,...
Neuropsychiatric Disease and Treatment
July 12, 2023
Lucian Manu
Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis." This letter is not a rebuttal to the article but, rather, a response to further clarify a few points on the real-world use of ketamine and esketamine.
International Clinical Psychopharmacology
July 11, 2023
Lucas Arrighi, Eloïse Maakaron, Théo Korchia et al.
About 30% of patients with major depressive disorder have treatment-resistant depression (TRD). Recently, intranasal esketamine was approved as a treatment option after the failure of two antidepressant trials. We report a patient with multiresistant depression that was successfully and safely treated with esketamine nasal spray. This 31-year-old inpatient with severe, chronic, and multi-TRD...